Therapeutic Enzymes Market Size, Share & Industry Analysis, By Product Type (Asparaginase, Streptokinase, Lipase, Collagenase, Lysozyme, Others), By Application (Leukemia, Antiviral Therapy, Stomach Disorders, Skin Ulcers, Others), By End-user (Hospitals, Clinics, Research Laboratories, Others) and Regional Forecast, 2024-2032

Enzymes or biocatalysts are produces in the human body from amino acids that the body obtains by digesting food proteins. Therapeutic enzymes are the special type of enzymes that are used for medical purposes either in their conjucation or isolated form. These enzymes have a broad variety of uses as thrombolytics, oncolytics, anticoagulants, or as replacements for some metabolic deficiencies. Rising patient pool for leukemia, other cancers, cardiovascular diseases, skin ulcer, etc., growing sedentary lifestyle responsible for increasing stress and subsequently giving rise to diseases, and improving healthcare services are some of the factors that are contributing to drive the therapeutic enzymes market growth during the forecast period. For instance, according to the National Cancer Institute, in 2017, around 434,982 people suffered from leukemia in US.

The overall therapeutic enzymes market is expected to witness remarkable growth during the forecast period due to factors such as rising patient pool for diseases such as leukemia, other cancers, cardiovascular diseases, skin ulcer, etc., and growing sedentary lifestyle responsible for increasing stress and subsequently giving rise to diseases. However, availability of alternate options for therapeutic enzyme therapy at lower cost is one of the major restraint of the market during the forecast period.

Market Segmentation:

Globally, the therapeutic enzymes market can be segmented on the bases of the product type, application, end-users, and region. Based on the product type the market can be segmented into asparaginase, streptokinase, lipase, collagenase, lysozyme, and others. Based on the application, the market can be segmented into leukemia, antiviral therapy, stomach disorders, skin ulcers, and others. Based on the end-users, the market can be segmented into hospitals, clinics, research laboratories, and others. Geographically, the therapeutic enzymes market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Key Players Covered:

Some of the major companies that are present in the therapeutic enzymes market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Codexis., DSM, Novozymes, and other prominent players.

Key Insights:

• Prevalence of Key Indications by Major Countries/Region


• New Product Launches


• Key Industry Trends


• Key Industry Developments Mergers, Acquisitions, And Collaborations

Regional Analysis:

Geographically, the therapeutic enzymes market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to lead the therapeutic enzymes market owing to the highly improved and advanced healthcare services, rising prevalence of leukemia along with growing awareness among the population. In Europe, the market is projected to expand owing to the development of novel therapeutic enzyme therapy and partnership activities of major market players. For instance, in January 2020, Codexis and Nestlé Health Science entered into a strategic collaboration with an aim to discover new enzyme therapy for potential treatment for GI disorders. Asia Pacific, on the other hand, is anticipated to grow with a remarkable growth rate due to an increasing patient pool of cancers and diseases requiring the therapeutic enzyme therapy.

The market in Latin America and the Middle East & Africa is likely to have a moderate growth during the forecast period owing to the rising patient awareness about therapeutic enzymes and growing governmental and non-governmental initiatives for improving the healthcare infrastructure.

Segmentation

Therapeutic Enzymes Market Industry Developments

• In January 2020, Codexis and Nestlé Health Science entered into a strategic collaboration with an aim to discover new enzyme therapy for potential treatment for GI disorders.


• In October 2018, Leadiant Biosciences, Inc. Received the USFDA approval for Revcovi, a enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.